Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tumor infiltrating lymphocytes + fludarabine + cyclophosphamide + interleukin-2
- Development stage
- Unknown
- Lead developer
- Iovance Biotherapeutics
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy that uses a patient's own tumor infiltrating lymphocytes (TILs) expanded in the laboratory, preceded by lymphodepleting chemotherapy with fludarabine and cyclophosphamide, and followed by interleukin-2 administration. This approach enhances the ability of TILs to recognize and attack cancer cells throughout the body.
- Other names
- TIL therapy with lymphodepletion and IL-2Adoptive cell transfer with lymphodepletion
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)DNA-directed primase/polymerase protein (PrimPol)RNR (Ribonucleotide reductase)DNA polymerase familyDNAMHC I (MHC class I})
Beyond the preview
Go deeper on tumor infiltrating lymphocytes + fludarabine + cyclophosphamide + interleukin-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tumor infiltrating lymphocytes + fludarabine + cyclophosphamide + interleukin-2.